ProPhase Labs, Inc. Inventory Valuation Reserves
ProPhase Labs, Inc. (PRPH) had Inventory Valuation Reserves of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Assets › Assets, Current › Inventory, Net
us-gaap:InventoryValuationReserves · last filed 2026-06-01
- 2025-12-31: Inventory Valuation Reserves $0.00.
- 2024-12-31: Inventory Valuation Reserves $8.00K.
- 2023-12-31: Inventory Valuation Reserves $219.00K; Inventory Valuation Reserves as first filed $258.00K.
- 2022-12-31: Inventory Valuation Reserves $512.00K.
| Period end | Inventory Valuation Reserves | Inventory Valuation Reserves as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 | |
| 2024-12-31 | $8.00K 10-K · filed 2026-06-01 | |
| 2023-12-31 | $219.00K 10-K · filed 2025-04-01 | $258.00K 10-K · filed 2024-03-29 |
| 2022-12-31 | $512.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $255.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $431.00K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $459.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $435.00K 10-K · filed 2023-03-29 | |
| 2020-12-31 | $167.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |